跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
VYNDAQEL 20 MG CAPSULAS BLANDAS - CIMA-AEMPS Drug Approval Details
Approvals
/
CIMA-AEMPS
/
VYNDAQEL 20 MG CAPSULAS BLANDAS
Approved
STANDARD
VYNDAQEL 20 MG CAPSULAS BLANDAS
Pfizer Europe Ma Eeig
🇪🇸 Spanish Agency of Medicines and Medical Devices
Approval Date
Nov 2, 2020
Approval ID
bcb040774e3382b4
Company
Pfizer Europe Ma Eeig
Type
Standard
Approval Details
Approval Id
bcb040774e3382b4
Drug Cima Aemps Name
VYNDAQEL 20 MG CAPSULAS BLANDAS
Register Number
11717001IP
Holder Company Name
Pfizer Europe Ma Eeig
Marketing Company Name
Abacus Medicine A/S
Holder Company Detail Path
/organization/pfizer-europe-ma-eeig
Authorization Date
2020-11-02
Dosage Form
CÁPSULA BLANDA
Dose
12,2 mg tafamidis
Route Of Administration
VÍA ORAL
Prescription Type
Uso Hospitalario
Commercialized
No
Company Name
Pfizer Europe Ma Eeig
Company Detail Path
/organization/pfizer-europe-ma-eeig
Company Information
Pharmaceutical Company Name
Pfizer Europe MA EEIG
Country Name
United Kingdom
Active Ingredients
TAFAMIDIS MEGLUMINA
20 mg
Approved
Quick Info
Agency
CIMA-AEMPS
Country
🇪🇸
Approval Date
Nov 2, 2020
Approval ID
bcb040774e3382b4
Type
Standard
Back to CIMA-AEMPS Approvals